Home InterVene Inc.

InterVene Inc.

    InterVene Raises $15 Million in Series B Funding

    The company’s BlueLeaf® Endovenous Valve Formation System is the first catheter-based solution for deep vein reflux (DVR) -- the failure of venous valves in the legs -- that does not require an implant.

    RECENT COMMENTS